Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Severe Hyponatremia in a Single-Center Series of 84 Homogenously Treated Children With Acute Lymphoblastic Leukemia

Janczar, Szymon MD, PhD; Zalewska-Szewczyk, Beata MD, PhD; Mlynarski, Wojciech MD, PhD

Journal of Pediatric Hematology/Oncology: March 2017 - Volume 39 - Issue 2 - p e54–e58
doi: 10.1097/MPH.0000000000000758
Online Articles: Original Articles

Electrolyte abnormalities are hallmark metabolic disturbances during the treatment of acute lymphoblastic leukemia (ALL). Hyponatremia is an ominous laboratory sign in the setting of neoplasia. We analyzed the incidence, risk factors, associations, specific interventions and outcomes of severe hyponatremia in a single-center series of children with ALL. The incidence of severe hyponatremia, defined as serum sodium levels below 130 mmol/L on at least 2 of 3 consecutive days, was 11.9%. History of hyponatremia episode is associated with neurologic complications (P=0.023) and the presence of overt central nervous system leukemia (CNS3) at diagnosis (P=0.005). Most observed hyponatremia episodes resolved relatively quickly, rarely requiring specific treatment. All but 1 hyponatremia episodes occurred in the induction or reinduction phases, but none before the administration of cytotoxic drugs, pointing to the role of therapy complications rather than leukemia per se. Most patients received vincristine shortly before hyponatremia onset, and vincristine has been previously strongly implicated in hyponatremia. We also suggest a role for imatinib. Although every patient with severe hyponatremia requires swift and thorough diagnostics a serious sequelae in the setting of pediatric ALL is rare. Hyponatremia association with neurotoxicity likely points to vincristine hypersensitivity in the subgroup of patients with both complications.

Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Lodz, Poland

The authors declare no conflict of interest.

Reprints: Szymon Janczar, MD, PhD, Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Sporna 36/50, Lodz 91-738, Poland (e-mail:

Received February 12, 2016

Accepted December 5, 2016

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.